Now I have a thorough understanding of the paper and can verify each claim. Let me write the final consolidated review.

## Summary

The paper proposes a three-component framework for the cold start problem in biomedical image classification: (1) self-supervised pretraining (SimCLR) to learn a meaningful latent space from unlabeled data, (2) farthest-point sampling (FPS) to select a diverse initial annotation set, and (3) model soups (weight averaging across learning rates) to overcome the absence of a validation set. Experiments on four biomedical datasets (Matek, ISIC, Retinopathy, Jurkat) show that FPS-based sampling generally outperforms random selection and k-means-based variants, while comparisons are drawn against the prior state-of-the-art Cold PAWS.

## Strengths

- **Demonstrates FPS as a consistently effective sampling strategy across diverse biomedical domains.** Table 1 and Figure 4 show that FPS achieves the highest F1-macro on three of four datasets (Matek, ISIC, Retinopathy) and consistently outperforms k-means-based cluster sampling variants across a wide range of cluster counts. The Matek leukemia dataset shows a particularly clear margin (FPS 0.69±0.06 vs. random 0.55±0.06).

- **Systematic comparison of three SSL backbones (SimCLR, SwAV, DINO) identifies the best fit for biomedical data.** Figures 3 and 5 provide both qualitative (UMAP) and quantitative (downstream F1-macro) evidence that SimCLR yields superior latent representations for cold-start sampling on these datasets. This offers practical guidance for practitioners in the domain.

- **Model soups provides a principled solution to the missing-validation-set problem.** Figure 6 demonstrates that weight averaging across learning rates (0.1, 0.01, 0.001) consistently improves over any single learning rate — e.g., on Matek from ~0.55 to ~0.7. This is a clean adaptation of an existing technique to a genuine cold-start constraint.

- **Class coverage analysis (Table 2) directly supports the diversity claim.** FPS achieves the highest or near-highest class coverage on all datasets (e.g., 13.6/15 classes on Matek vs. 9.8 for random), providing a concrete link between the sampling strategy's diversity and downstream classification performance.

- **Evaluation on four diverse, realistic biomedical datasets** spanning microscopy (Matek, Jurkat), dermatoscopy (ISIC), and fundus photography (Retinopathy), with varying sizes (3.6k–32k) and class counts (5–15). The consistent pattern of results supports generalizability claims.

## Weaknesses

### Fatal
None.

### Major

- **The comparison with Cold PAWS (the state-of-the-art baseline) is conducted on an ablated version without its semi-supervised learning component, which undermines the central claim of "outperforming the state-of-the-art."** The authors state (Section 4.2): *"Our implementation does not incorporate a semi-supervised approach on top of it; instead, we solely rely on labeled data for training the classifier head."* Cold PAWS is an integrated pipeline where the sampling step (k-medoids on t-SNE) was designed to work in concert with subsequent semi-supervised training. By discarding that phase and still presenting results as "outperforming Cold PAWS," the comparison conflates sampling strategy with the overall method. The paper's abstract and conclusion frame the contribution as beating the full state-of-the-art, but what is actually compared is FPS + standard classifier head vs. Cold PAWS's sampling + standard classifier head. A proper comparison should either (a) test both full pipelines end-to-end, or (b) explicitly frame the contribution as a better *sampling strategy* (not a better overall cold-start solution) versus the Cold PAWS sampling component. This is not an unfixable problem — the empirical comparison of sampling strategies is still informative — but the current framing overclaims.

### Minor

- **Statistical significance is not assessed, and several reported improvements are marginal.** Results are reported as means ± std from only 5 runs, with no statistical tests (t-tests, confidence intervals, or bootstrapping). Examining the text and Table 1, some comparisons show overlapping or near-overlapping error bars — e.g., on Retinopathy (FPS 0.33±0.04 vs. random 0.30±0.03) and Jurkat (FPS 0.57±0.04 vs. random 0.56±0.04). While the Matek gap is clear (0.69 vs. 0.55), the paper's language ("outperforms on all datasets") treats all comparisons as equally strong. Providing confidence intervals or p-values would substantially strengthen the claims.

- **The claim that "Cold PAWS utilizes the testing dataset for early stopping, potentially introducing information leakage" (Section 4.3, Ablation study) is made without any citation or evidence.** The paper provides no reference to a specific page, equation, or section of the Cold PAWS paper (Mannix & Bondell, 2023) supporting this allegation. Even softened with "potentially," this is a serious claim about another method's evaluation integrity and should either be supported with a direct citation or removed.

- **Inconsistency between abstract and Table 3 regarding the speedup factor.** The abstract claims "8 times faster performance," while the caption of Table 3 states "FPS is five times faster than this state-of-the-art." These are different figures. More substantively, the speed advantage is reported for *sampling time only*, but the end-to-end pipeline includes a non-trivial SSL pretraining step (which is common to both methods being compared). The abstract's "8× faster" phrasing could easily be misinterpreted as end-to-end speedup.

- **Limited discussion of FPS sensitivity to the randomly chosen first point.** Since FPS selects its first point randomly (Section 2), different runs could theoretically produce very different annotation sets. While the reported standard deviations are relatively low, a brief discussion or ablation (e.g., varying the first-seed) would strengthen confidence in the method's robustness.

### Trivial
- The paper states in the abstract that "none of the previous studies have applied their methods to the biomedical domain" (line 30), but the paper cites Chandra et al. (2021), Jin et al. (2022), and Yi et al. (2022) who all work on cold start — some of these may use biomedical-adjacent data. This overstatement should be qualified.

## Nice-to-Haves

- **Including a comparison with an uncertainty-based or coreset selection baseline** (e.g., Sener & Savarese 2018) would strengthen the claim that FPS is a strong sampling approach relative to other principled selection strategies beyond k-means variants and Cold PAWS. Not required for the current scope, but would be a valuable addition.

- **Releasing code/implementation** would support reproducibility, though it is not required. The method is simple to describe, which partially mitigates this.

- **Quantifying the quality of the SimCLR latent space** via a linear probe evaluation on the full dataset (rather than just the UMAP visualization in Figure 3) would provide a clearer, independent measure of representation quality.

## Removed Points

These points were raised by reviewers but are removed or downgraded per policy:

1. **"Missing comparison with Wang et al. (2022)"** — The paper explicitly states this comparison was omitted due to source code unavailability (line 107). This is a legitimate practical constraint, not a methodological flaw. The paper still compares against Cold PAWS and multiple k-means baselines.

2. **"No code or data is released"** — The paper does not promise code release, and per policy, questioning availability of unreleased resources is not a valid weakness. Moved to Nice-to-Haves as a suggestion.

3. **"Limited novelty — components are all existing techniques"** — This is a valid observation about framing but not a structural weakness in an empirical application paper. The paper's contribution is in the combination and systematic evaluation for the biomedical cold-start problem, which it delivers. The reviewer's own framing acknowledges this is "acceptable for an application-oriented paper." Downgraded and folded into the novelty framing observation, not listed as a standalone weakness.

4. **"The paper should cover more tasks / domains"** — The paper already covers four diverse datasets. Asking for more is scope creep.

## Novel Insights

The reviews surface an interesting tension not fully resolved by the paper: the Cold PAWS comparison issue highlights a deeper question in cold-start evaluation — should the method under test be compared against a competitor's full pipeline (including any semi-supervised components the competitor uses), or against an isolated component (e.g., just the sampling strategy)? The authors take the latter approach but frame their claims in the former language. This is a useful caution for the field: when evaluating cold-start methods that combine multiple stages (representation learning → sampling → classifier training → optional SSL), reviewers and authors should agree upfront on whether the benchmark compares *complete pipelines* or *individual modules* with the rest held constant, and the claims should match the chosen protocol.

## Suggestions

1. **Fix the Cold PAWS comparison.** Either (a) run the full Cold PAWS pipeline (with semi-supervised training) end-to-end and compare fairly, or (b) clearly reframe the contribution as "FPS is a superior sampling strategy" and rename the baseline accordingly (e.g., "Cold PAWS (sampling-only)"). Adjust all claims about "outperforming the state-of-the-art" to match whichever protocol is actually used.

2. **Provide a citation or remove the information-leakage claim about Cold PAWS.** If the Cold PAWS paper indeed uses the test set for early stopping, cite the specific section. If not, remove the statement entirely.

3. **Reconcile the "5×" vs. "8×" speed discrepancy** and clarify in the abstract that the speedup refers to sampling time only, not end-to-end training time.

4. **Add statistical significance measures** — at minimum bootstrapped 95% confidence intervals — for the key FPS vs. random and FPS vs. Cold PAWS comparisons, and qualify claims on datasets where margins are small.

5. **Add a brief discussion** of the effect of the random first-point selection in FPS, explaining why the observed standard deviations are low despite this stochastic element.

## Score and Decision

The paper tackles a practically important problem and provides a clean, reproducible framework with systematic experiments across four biomedical datasets. The core empirical finding — that FPS on SSL representations is a robust sampling strategy — is useful and well-supported by the class-coverage and k-means ablation experiments. However, the paper's central claim of "outperforming the state-of-the-art" rests on a comparison against an ablated version of Cold PAWS (missing its semi-supervised component), and several reported margins are small without statistical significance testing. The unsubstantiated claim about Cold PAWS information leakage further weakens credibility. These issues are addressable with revisions, but as submitted, the evidence does not fully support the strength of the claims made.

MY FINAL SCORE: <pineapple>4.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>